BioNTech Biotech company to release cancer vaccines by 2026

BioNTech biotech company was founded in 2008 by two Turks who moved to Germany and an Austrian oncologist. BioNTech, the manufacturer of the well-known COVID-19 vaccine, has announced its ambitious plan to release the world's first cancer vaccines by 2026. Ugur Shahin, one of the co-founders of the company, shared information about ongoing clinical trials that cover as many as 30 types of cancer, including skin, intestinal, uterine, prostate and lung cancers. According to him, the company has a goal to form a wide portfolio of cancer treatments by 2030.

BioNTech's progressive approach is based on the development of individual treatment methods that take into account the characteristics of each patient. The main objective of the company is to create vaccines that can help the immune system fight cancer cells, avoiding severe chemotherapeutic methods that can negatively affect overall health.

Ozlem Tureji, also co-founder of BioNTech, stressed that the company is committed to creating innovative vaccines that can stimulate immunity to self-destruction of cancerous tumors. This innovative approach can significantly change the paradigm of cancer treatment, providing more effective and less invasive methods to combat this disease.

The company plans to complete ongoing research and register 10 vaccine candidates by the end of this year. This will be an important step in the development of innovative drugs to fight cancer and open up new prospects in the treatment of this serious disease.